Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Epigenetically mediated gene silencing
- Process of DNA methylation
- Altered chromatin status in cancer
- Familial cancer genes
- Chromatin composition
- Screening the cancer genome
- Vogalstein paradigm
- Re-activated hypermethylated genes
- Hypothesis-early stage epigenetic gene silencing
- Epigenetic & genetic interaction in tumorigenesis
- sFRP genes - what are they?
- SFRP hypermethylation and CRC progression
- Epigenetic silencing of SFRPs in CRC
- Concept of cancer pathway addiction
- Collaboration in early colon tumorigenesis
- Heretical hypothesis
- Re-activated hypermethylated genes
- Screening the cancer genome
- HIC-1 is a candidate tumor suppressor gene
- HIC-1 hypermethylation in human cancer
- Targeted disruption of mouse Hic-1 gene
- Hic-1 as a tumor suppressor in mouse models
- Epigenetic and genetic interactions
- The full activities if HIC-1
- Properties of SIRT1
- Paradigm summary for HIC-1 P53 interaction
- Hypothesis review
- Translational implications
Topics Covered
- Introduction to epigenetic changes in cancer
- defining the process of promoter DNA hypermethylation as a constituent of a broad range of chromatin abnormalities in cancer
- defining the genes aberrantly silenced in cancer including approaches being used to screen the cancer genome for such genes
- defining what is known about the interaction of DNA methylation and chromatin modifications for initiating and maintaining gene silencing in cancer
- outlining the position of aberrant gene silencing in tumor progression and particularly highlighting the key role these changes may play for the earliest steps in tumorigenesis
- defining the potential for using DNA hypermethylated gene promoter sequences as molecular markers for cancer risk assessment, early diagnosis and prognosis
- discussing the possibilities for targeting reversal of gene silencing as a prevention and therapeutic strategy for cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Baylin, S. (2007, October 1). Epigenetically mediated gene silencing: a companion to genetic alterations in driving tumorigenesis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/VRTX2257.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Stephen Baylin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Epigenetically mediated gene silencing: a companion to genetic alterations in driving tumorigenesis
A selection of talks on Biochemistry
Hide